

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.	10/515,934
		FILING DATE	May 19, 2006
		APPLICANT	Mercep et al.
		GROUP	1614
		EXAMINER	A.M. Lewis
		ATTORNEY DOCKET NO.	PLP529USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	3,773,940	11/20/1973	Schindler et al.			
	2	3,781,294	Dec. 25, 1973	Lombardino			
	3	3,859,439	01/07/1975	Blattner and Schindler			
	4	4,112,110	09/15/1978	Blattner			
	5	4,271,179	06/02/1981	van der Burg			
	6	4,267,190	05/12/1981	Cherkofsky et al.			
	7	4,267,184	05/12/1981	Cherkofsky et al.			
	8	7,312,203	12/25/2007	Mercep et al.			
	9	7,435,834	October 2008	Mercep et al.			
	10	US 2005/0148578	07/05/2005	Mercep et al.			

Continue on page _____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	11	EP 0125484	11/21/1984	Ciba Geigy AG			
	12	EP 0357126	03/07/1990	Akzo N.V.			
	13	HR 20000310	Feb. 28, 2002	CROATIA			X
	14	WO 91/18885	Dec. 12, 1991	WIPO			
	15	WO 98/54186	12/03/1998	Akzo Nobel N.V.			
	16	WO 01/87890	Nov. 22, 2001	WIPO			
	17	WO 03/097648	11/27/2003	Pliva d.d.			

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

18	Badger et al. "Pharmacological profile of SB-203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function." <i>J. Pharmac. Env. Therap.</i> , 1996, 279(3)):1453-1461.
19	Bennett et al. "Reaction of 5-acetyl-10, didehydro-5H-dibenz[b,f] azepine with pyrrole, N-methylpyrrole, imadazole and n-methylimidazole: cycloaddition versus Michael addition." <i>J. Heterocycl. Chem.</i> , 1994, 31:293-296.
20	Bresnihan. "Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA); results of randomized double-blind, placebo-controlled multicenter trial." <i>Arthritis Rheum.</i> , 1996, 39:73.
21	Carswell et al. "An endotoxin-induced serum factor that causes necrosis of tumors." <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1975, 72:3666-3670.
22	Collier et al. "The abdominal constriction response and its suppression by analgesic drugs in the mouse." <i>Br. J. Pharmac. Chemother.</i> , 1968, 32:295-310
23	Dinarello. "An update on human interleukin-1: From molecular biology to clinical relevance." <i>J. Clinical Immunology</i> , 1985, 5:287.
24	Dinarello. "Interleukin-1." <i>Rev. Infect. Disease</i> , 1984, 6(1):51-95.
25	Elliott et al. "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis." <i>The Lancet</i> , 1994, 344:1105-1110.
26	Fukawa et al. "A method for evaluating analgesic agents in rats." <i>J. Pharmacol. Meth.</i> , 1980, 4:251-259.
27	Funke et al. "Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine Maleate. <i>Arzheim-Forsch.</i> , 1190, 40:536-539.
28	Georgopoulos et al. "Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice." <i>J. Inflamm.</i> , 1996, 46:86-97.
29	Keffler, et al. "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis." <i>EMBO J.</i> , 1991, 10:4025-4031.

	30	Mattioli and Ghia. "Omega-dialkylaminoalkyl ethers of phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity." <i>J. Heterocyclic Chem.</i> , 1997, 34:963-968.
	31	Mori et al. "Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice." <i>J. Immunol.</i> , 1996, 157:3178-3182.
	32	Novacek et al. "Reaction of 8-chloro-10-phenylhydrazono-10, 11-dihydro-dibenzo[b,f]thepine with aromatic aldehydes." <i>Collection Czechoslov. Chem. Commun.</i> , 1976, Vol. 41, 785-787.
	33	Pfeffer et al. "Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to <i>L. monocytogenes</i> infection." <i>Cell</i> , 1993, 73:457-467.
	34	Schulz et al. "Synthese von 1,3a,3,12b-tetrahydro-dibenzo[b,f]-pyrazolo[3,4-d]azepin-Derivaten." <i>Z. Chem.</i> 1988, 28:181-182.
	35	Schweizer et al. "Combined automated writhing/motility test for testing analgesics." <i>Agents and Actions</i> , 1988, 23:29-31.
	36	Van Assche and Rutgeerts. "Anti-TNF agents in Crohn's disease." <i>Exp. Opin. Invest. Drugs</i> , 2000, 9:103-111.
	37	Wermuth et al. "Molecular Variations Based on Isosteric Replacements." <i>Practice of Medicinal Chemistry</i> , 1996, pages 203-237.

Continue on page _____

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.